Trial Profile
Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Pharmacokinetics
- Acronyms CANCUN
- Sponsors Baxalta; Shire; Takeda
- 14 Sep 2020 Status changed from recruiting to completed.
- 18 Dec 2019 Planned End Date changed from 31 Jan 2020 to 30 Jul 2020.
- 18 Dec 2019 Planned primary completion date changed from 31 Jan 2020 to 30 Jul 2020.